PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
PACBNasdaqHealthcare · Laboratory Analytical Instruments · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $160.0M | $154.0M | $200.5M | $128.3M | $130.5M | $78.9M |
| Operating income | −$553.9M | −$474.3M | −$334.5M | −$307.2M | −$210.4M | −$104.4M |
| Net income | −$546.4M | −$309.9M | −$306.7M | −$314.2M | −$181.2M | $29.4M |
| Total assets | $784.1M | $1.26B | $1.75B | $1.77B | $2.01B | $414.0M |
| Total liabilities | $778.7M | $753.9M | $1.04B | $1.20B | $1.22B | $78.5M |
| Equity | $5.3M | $506.6M | $701.3M | $562.9M | $791.0M | $335.5M |
| EPS (diluted) | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 | $0.17 |
| Shares out. | 297.9M | 268.0M | 247.1M | 221.2M | 193.1M | 153.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −346.2%
- Net margin
- −341.5%
- Return on equity
- −10214.5%
- Return on assets
- −69.7%
- Return on capital (ROCE)
- −77.9%
- Liabilities / assets
- 99.3%
- Debt / equity
- 145.58×
- Book value / share
- $0.02
- Revenue growth (YoY)
- 3.9%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -13.42distress
- Accruals / assets
- −55.5%clean
- Beneish M-Score
- -5.16normal
- Piotroski F-Score
- 2/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Group IncPassive (13G)Mar 27, 2026
- Ark Investment Management LlcPassive (13G)Feb 3, 2026
- Madrone Capital Partners, LlcPassive (13G)Nov 14, 2025
- Edmond De Rothschild Asset ManagementPassive (13G)Jul 24, 2025
- Blackrock, Inc.Passive (13G)Apr 17, 2025
- Millennium Management LlcPassive (13G)Apr 9, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 59.9M | 9.0 | +27.3% |
| Apr 30, 2026 | 47.1M | 7.0 | +1.6% |
| Apr 15, 2026 | 46.4M | 8.4 | +1.6% |
| Mar 31, 2026 | 45.6M | 8.4 | +10.3% |
| Mar 13, 2026 | 41.4M | 6.6 | +8.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 7, 2026
- Director / officer change · Regulation FD disclosureMar 6, 2026
- Director / officer change · Regulation FD disclosureMar 5, 2026
- Results of operationsFeb 12, 2026
- Director / officer changeFeb 3, 2026
- Entered a material agreement · Completed an acquisition or disposition · Regulation FD disclosureFeb 2, 2026
- Results of operations · Other material eventJan 12, 2026
- Results of operationsNov 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.